Elemental IV is building an automation-led GMP manufacturing platform for the ready-to-use injectable medicines Australia's hospitals can no longer afford to import-depend on — a complementary domestic source of supply for the products most exposed to shortage.
Australia imports ~90% of its prescription medicines. When global supply breaks, hospitals ration. We're building the missing domestic capability — capital-efficient, automated, and policy-aligned.
The 2024 IV-fluid crisis exposed how concentrated Australia's sterile-medicine supply has become. The acute crisis passed — but the vulnerability across electrolytes, antibiotics and ICU infusions remains. For the first time in a decade, the policy and capital environment is aligned to fix it.
Only one large-scale domestic IV-fluid manufacturer operates at meaningful scale. The rest of the sterile formulary is met through imports, manual hospital compounding, or Section 19A approvals priced 2–5× above domestic equivalents.
Sovereign manufacturing is now active federal policy. The National Reconstruction Fund (A$15B) names Medical Science a priority sector, alongside Modern Manufacturing grants and South Australian co-investment programs.
Automated sterile fill-finish is now standard internationally — yet most Australian sterile compounding remains manual. We pair validated automation with disciplined Australian GMP execution, at scale.
Hospital demand for sterile injectables is recurrent, growing with an ageing population, and procured on reliability and quality rather than price alone. Our serviceable entry point is sized bottom-up from acute hospital admissions.
A modular GMP facility in Adelaide, anchored by an equipment and technical partnership with global sterile-consumables manufacturer Epic Medical — engineered for speed-to-licensure and scalable output.
ISO 7/8 cleanrooms and TGA-aligned quality systems in a refit facility, sized for staged expansion rather than a single oversized capital outlay.
Automated SmartFill filling technology contributed by Epic Medical, plus technical integration support and a preferred-supplier arrangement for sterile consumables.
Higher sterility assurance, consistent quality and the throughput that point-of-use manual compounding can't deliver — the core efficiency advantage.
Phase 1 high-frequency products fund and de-risk the platform before expanding into higher-value shortage-list injectables on the same GMP licence.
A disciplined SKU strategy: anchor on the highest-frequency hospital injectables, then move into the specific products on the TGA's active shortage list where margins and supply security are strongest.
Consistent, ready-to-use supply that replaces labour-intensive manual preparation.
Products currently in recurring shortage — the highest-margin, highest-resilience opportunity.
FY28 is a validation year. As shifts extend and the higher-value Phase 2 mix comes online, revenue compounds while fixed costs grow modestly — lifting gross margin and turning EBITDA positive.
Base case. Full integrated financial model and use-of-funds detail available to qualified investors under NDA.
Asset-backed, with recurring institutional demand and a manufacturing-style return profile. Suited to healthcare specialists, family offices, co-investment funds and strategic partners.
Hospital injectables are consumed continuously and procured on reliability — not discretionary spend.
GMP licensing, validation and TGA registration create a defensible moat once cleared.
NRF, Modern Manufacturing and SA state programs are designed for exactly this profile — pursued in parallel with equity.
Year 4–7 via strategic acquisition, partnership, or an operating-yield platform.
A sequenced raise that capitalises validated milestones rather than promises.
We're speaking with healthcare-focused investors, family offices and strategic partners. Request the full business plan and integrated financial model.